AKT1 and osteosarcoma: The observation demonstrated that AKT-SOX2 is responsible for the sensitivity of cisplatin in OS cells and underscores the potential therapeutic benefit of targeting the AKT-SOX2 axis in the treatment of osteosarcoma.